PRESS-RELEASE filed Nov 12, 2026 at 16:05 ET
Pliant Therapeutics reported Q3 2026 net loss of $24.4M ($0.39 per share), slightly narrower than the $26.3M loss a year ago, while revenue remained zero. The company highlighted strong enrollment in its FORTIFY Phase 1b trial for PLN-101095 and initial preclinical data for its integrin-mediated drug delivery platform. With $142.6M in cash, operations are funded to mid-2028, but the stock's $49M market cap reflects the high-risk, pre-revenue stage.